Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous stem cell transplant. The French pharmaceutical company said Sarclisa was approved in combination with bortezomib, lenalidomide and dexamethasone.
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ...
GlobalData on MSN1mon
Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trialSanofi’s Sarclisa (isatuximab) plus standard of care has been shown to extend the time that some multiple myeloma patients ...
Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...
Evorpacept is ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated Fc domain and SARCLISA is Sanofi’s ...
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback